Log In
Print
BCIQ
Print
Print this Print this
 

Invokamet, Vokanamet, Canagliflozin/metformin IR

  Manage Alerts
Collapse Summary General Information
Company Mitsubishi Tanabe Pharma Corp.
DescriptionFixed-dose combination of canagliflozin, an sodium-glucose cotransporter 2 (SGLT2) inhibitor, and immediate-release metformin
Molecular Target Sodium-glucose cotransporter 2 (SGLT2)
Mechanism of ActionSodium-glucose cotransporter 2 (SGLT2) inhibitor
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentApproved
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation

U.S. - Undisclosed Review (Treat Type II diabetes);
EU - Standard Review (Treat Type II diabetes)

Partner

Johnson & Johnson


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today